<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20231012081516&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20231012081516&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 12 Oct 2023 12:15:18 +0000</lastbuilddate>
<pubDate>Thu, 12 Oct 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Disrupted Functional Brain Connectome in the Fetus With Congenital Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37823309/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Oct 12. doi: 10.1161/CIRCRESAHA.123.323276. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37823309/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37823309</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323276>10.1161/CIRCRESAHA.123.323276</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37823309</guid>
<pubDate>Thu, 12 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Josepheen De Asis-Cruz</dc:creator>
<dc:creator>Nickie Andescavage</dc:creator>
<dc:creator>Mary T Donofrio</dc:creator>
<dc:creator>Gilbert Vezina</dc:creator>
<dc:creator>David Wessel</dc:creator>
<dc:creator>Adre du Plessis</dc:creator>
<dc:creator>Catherine Limperopoulos</dc:creator>
<dc:date>2023-10-12</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Disrupted Functional Brain Connectome in the Fetus With Congenital Heart Disease</dc:title>
<dc:identifier>pmid:37823309</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323276</dc:identifier>
</item>
<item>
<title>Single-Nuclei RNA-Sequencing of the Gastrocnemius Muscle in Peripheral Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37823262/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: This reference single-nuclei RNA-sequencing atlas provides a comprehensive analysis of the cell composition, transcriptional signature, and intercellular communication pathways that are altered in the PAD condition.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Oct 12. doi: 10.1161/CIRCRESAHA.123.323161. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Lower extremity peripheral artery disease (PAD) is a growing epidemic with limited effective treatment options. Here, we provide a single-nuclei atlas of PAD limb muscle to facilitate a better understanding of the composition of cells and transcriptional differences that comprise the diseased limb muscle.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We obtained gastrocnemius muscle specimens from 20 patients with PAD and 12 non-PAD controls. Nuclei were isolated and single-nuclei RNA-sequencing was performed. The composition of nuclei was characterized by iterative clustering via principal component analysis, differential expression analysis, and the use of known marker genes. Bioinformatics analysis was performed to determine differences in gene expression between PAD and non-PAD nuclei, as well as subsequent analysis of intercellular signaling networks. Additional histological analyses of muscle specimens accompany the single-nuclei RNA-sequencing atlas.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Single-nuclei RNA-sequencing analysis indicated a fiber type shift with patients with PAD having fewer type I (slow/oxidative) and more type II (fast/glycolytic) myonuclei compared with non-PAD, which was confirmed using immunostaining of muscle specimens. Myonuclei from PAD displayed global upregulation of genes involved in stress response, autophagy, hypoxia, and atrophy. Subclustering of myonuclei also identified populations that were unique to PAD muscle characterized by metabolic dysregulation. PAD muscles also displayed unique transcriptional profiles and increased diversity of transcriptomes in muscle stem cells, regenerating myonuclei, and fibro-adipogenic progenitor cells. Analysis of intercellular communication networks revealed fibro-adipogenic progenitors as a major signaling hub in PAD muscle, as well as deficiencies in angiogenic and bone morphogenetic protein signaling which may contribute to poor limb function in PAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This reference single-nuclei RNA-sequencing atlas provides a comprehensive analysis of the cell composition, transcriptional signature, and intercellular communication pathways that are altered in the PAD condition.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37823262/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37823262</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323161>10.1161/CIRCRESAHA.123.323161</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37823262</guid>
<pubDate>Thu, 12 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Caroline Pass</dc:creator>
<dc:creator>Victoria Palzkill</dc:creator>
<dc:creator>Jianna Tan</dc:creator>
<dc:creator>Kyoungrae Kim</dc:creator>
<dc:creator>Trace Thome</dc:creator>
<dc:creator>Qingping Yang</dc:creator>
<dc:creator>Brian Fazzone</dc:creator>
<dc:creator>Scott T Robinson</dc:creator>
<dc:creator>Kerri A O'Malley</dc:creator>
<dc:creator>Feng Yue</dc:creator>
<dc:creator>Salvatore T Scali</dc:creator>
<dc:creator>Scott A Berceli</dc:creator>
<dc:creator>Terence E Ryan</dc:creator>
<dc:date>2023-10-12</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Single-Nuclei RNA-Sequencing of the Gastrocnemius Muscle in Peripheral Artery Disease</dc:title>
<dc:identifier>pmid:37823262</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323161</dc:identifier>
</item>
<item>
<title>Acute coronary syndromes: new guidelines and new light shed on biomarkers and mechanisms of plaque instability</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37822014/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 12;44(38):3707-3711. doi: 10.1093/eurheartj/ehad656.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37822014/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37822014</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad656>10.1093/eurheartj/ehad656</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37822014</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Acute coronary syndromes: new guidelines and new light shed on biomarkers and mechanisms of plaque instability</dc:title>
<dc:identifier>pmid:37822014</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad656</dc:identifier>
</item>
<item>
<title>Socioeconomic inequalities in cardiovascular disease: a causal perspective</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37821646/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>Socioeconomic inequalities in cardiovascular disease (CVD) persist in high-income countries despite marked overall declines in CVD-related morbidity and mortality. After decades of research, the field has struggled to unequivocally answer a crucial question: is the association between low socioeconomic position (SEP) and the development of CVD causal? We review relevant evidence from various study designs and disciplinary perspectives. Traditional observational, family-based and Mendelian...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Oct 11. doi: 10.1038/s41569-023-00941-8. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Socioeconomic inequalities in cardiovascular disease (CVD) persist in high-income countries despite marked overall declines in CVD-related morbidity and mortality. After decades of research, the field has struggled to unequivocally answer a crucial question: is the association between low socioeconomic position (SEP) and the development of CVD causal? We review relevant evidence from various study designs and disciplinary perspectives. Traditional observational, family-based and Mendelian randomization studies support the widely accepted view that low SEP causally influences CVD. However, results from quasi-experimental and experimental studies are both limited and equivocal. While more experimental and quasi-experimental studies are needed to aid causal understanding and inform policy, high-quality descriptive studies are also required to document inequalities, investigate their contextual dependence and consider SEP throughout the lifespan; no simple hierarchy of evidence exists for an exposure as complex as SEP. The COVID-19 pandemic illustrates the context-dependent nature of CVD inequalities, with the generation of potentially new causal pathways linking SEP and CVD. The linked goals of understanding the causal nature of SEP and CVD associations, their contextual dependence, and their remediation by policy interventions necessitate a detailed understanding of society, its change over time and the phenotypes of CVD. Interdisciplinary research is therefore key to advancing both causal understanding and policy translation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37821646/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37821646</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00941-8>10.1038/s41569-023-00941-8</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37821646</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>David Bann</dc:creator>
<dc:creator>Liam Wright</dc:creator>
<dc:creator>Alun Hughes</dc:creator>
<dc:creator>Nish Chaturvedi</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Socioeconomic inequalities in cardiovascular disease: a causal perspective</dc:title>
<dc:identifier>pmid:37821646</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00941-8</dc:identifier>
</item>
<item>
<title>Reply: Understanding the Transplant Recipient Implications of Hearts From Donors With Active COVID-19</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37821179/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 17;82(16):e149. doi: 10.1016/j.jacc.2023.08.018.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37821179/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37821179</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.018>10.1016/j.jacc.2023.08.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37821179</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Shivank Madan</dc:creator>
<dc:creator>Ulrich P Jorde</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Understanding the Transplant Recipient Implications of Hearts From Donors With Active COVID-19</dc:title>
<dc:identifier>pmid:37821179</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.018</dc:identifier>
</item>
<item>
<title>Understanding the Transplant Recipient Implications of Hearts From Donors With Active COVID-19</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37821178/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 17;82(16):e147. doi: 10.1016/j.jacc.2023.07.032.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37821178/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37821178</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.032>10.1016/j.jacc.2023.07.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37821178</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Ricardo M La Hoz</dc:creator>
<dc:creator>Justin L Grodin</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Understanding the Transplant Recipient Implications of Hearts From Donors With Active COVID-19</dc:title>
<dc:identifier>pmid:37821178</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.032</dc:identifier>
</item>
<item>
<title>Reply: Similarities to Pacing-Induced Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37821177/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 17;82(16):e145. doi: 10.1016/j.jacc.2023.07.030.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37821177/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37821177</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.030>10.1016/j.jacc.2023.07.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37821177</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jan-Christian Reil</dc:creator>
<dc:creator>Ingo Eitel</dc:creator>
<dc:creator>Thomas Stiermaier</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Similarities to Pacing-Induced Heart Failure</dc:title>
<dc:identifier>pmid:37821177</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.030</dc:identifier>
</item>
<item>
<title>Similarities to Pacing-Induced Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37821176/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 17;82(16):e143. doi: 10.1016/j.jacc.2023.06.053.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37821176/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37821176</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.053>10.1016/j.jacc.2023.06.053</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37821176</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Kazuo Komamura</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Similarities to Pacing-Induced Heart Failure</dc:title>
<dc:identifier>pmid:37821176</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.053</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37821175/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 17;82(16):1648. doi: 10.1016/j.jacc.2023.09.001.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37821175/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37821175</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.001>10.1016/j.jacc.2023.09.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37821175</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:date>2023-10-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:37821175</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.001</dc:identifier>
</item>
<item>
<title>International Consensus on Differential Diagnosis and Management of Patients With Danon Disease: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37821174/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>Danon disease is a rare X-linked autophagic vacuolar cardioskeletal myopathy associated with severe heart failure that can be accompanied with extracardiac neurologic, skeletal, and ophthalmologic manifestations. It is caused by loss of function variants in the LAMP2 gene and is among the most severe and penetrant of the genetic cardiomyopathies. Most patients with Danon disease will experience symptomatic heart failure. Male individuals generally present earlier than women and die of either...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 17;82(16):1628-1647. doi: 10.1016/j.jacc.2023.08.014.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Danon disease is a rare X-linked autophagic vacuolar cardioskeletal myopathy associated with severe heart failure that can be accompanied with extracardiac neurologic, skeletal, and ophthalmologic manifestations. It is caused by loss of function variants in the LAMP2 gene and is among the most severe and penetrant of the genetic cardiomyopathies. Most patients with Danon disease will experience symptomatic heart failure. Male individuals generally present earlier than women and die of either heart failure or arrhythmia or receive a heart transplant by the third decade of life. Herein, the authors review the differential diagnosis of Danon disease, diagnostic criteria, natural history, management recommendations, and recent advances in treatment of this increasingly recognized and extremely morbid cardiomyopathy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37821174/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37821174</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.014>10.1016/j.jacc.2023.08.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37821174</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Kimberly N Hong</dc:creator>
<dc:creator>Emily A Eshraghian</dc:creator>
<dc:creator>Michael Arad</dc:creator>
<dc:creator>Alessia Argirò</dc:creator>
<dc:creator>Michela Brambatti</dc:creator>
<dc:creator>Quan Bui</dc:creator>
<dc:creator>Oren Caspi</dc:creator>
<dc:creator>Fernando de Frutos</dc:creator>
<dc:creator>Barry Greenberg</dc:creator>
<dc:creator>Carolyn Y Ho</dc:creator>
<dc:creator>Juan Pablo Kaski</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Matthew R G Taylor</dc:creator>
<dc:creator>Abigail Yesso</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:creator>Eric D Adler</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>International Consensus on Differential Diagnosis and Management of Patients With Danon Disease: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:37821174</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.014</dc:identifier>
</item>
<item>
<title>Altered In Utero Metabolic Brain Trajectories in CHD: Going Beyond Fetal Brain Structure and Physiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37821173/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 17;82(16):1624-1627. doi: 10.1016/j.jacc.2023.08.039.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37821173/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37821173</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.039>10.1016/j.jacc.2023.08.039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37821173</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Ashok Panigrahy</dc:creator>
<dc:creator>Stefan Blüml</dc:creator>
<dc:creator>Vidya Rajagopalan</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Altered In Utero Metabolic Brain Trajectories in CHD: Going Beyond Fetal Brain Structure and Physiology</dc:title>
<dc:identifier>pmid:37821173</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.039</dc:identifier>
</item>
<item>
<title>Magnetic Resonance Spectroscopy of Brain Metabolism in Fetuses With Congenital Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37821172/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: CHD is associated with altered cerebral metabolites in utero, particularly in the third trimester period of pregnancy, which is characterized by exponential brain growth and maturation, and is associated with survival to hospital discharge. The long-term neurodevelopmental consequences of these findings warrant further study.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 17;82(16):1614-1623. doi: 10.1016/j.jacc.2023.08.013.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Congenital heart disease (CHD) remains a significant risk factor for neurologic injury because altered fetal hemodynamics may be unable to support typical brain development during critical periods of growth and maturation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The primary objective was to assess differences in the cerebral biochemical profile between healthy fetuses and fetuses with complex CHD and to relate these with infant outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Pregnant participants underwent fetal magnetic resonance imaging with cerebral proton magnetic resonance spectroscopy acquisitions as part of a prospective observational study. Cerebral metabolites of N-acetyl aspartate, creatine, choline, myo-inositol, scyllo-inositol, lactate, and relevant ratios were quantified using LCModel.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We acquired 503 proton magnetic resonance spectroscopy images (controls = 333; CHD = 170) from 333 participants (controls = 221; CHD = 112). Mean choline levels were higher in CHD compared with controls (CHD 2.47 IU [Institutional Units] ± 0.44 and Controls 2.35 IU ± 0.45; P = 0.02), whereas N-acetyl aspartate:choline ratios were lower among CHD fetuses compared with controls (CHD 1.34 ± 0.40 IU vs controls 1.44 ± 0.48 IU; P = 0.001). Cerebral lactate was detected in all cohorts but increased in fetuses with transposition of the great arteries and single-ventricle CHD (median: 1.63 [IQR: 0.56-3.27] in transposition of the great arteries and median: 1.28 [IQR: 0-2.42] in single-ventricle CHD) compared with 2-ventricle CHD (median: 0.79 [IQR: 0-1.45]). Cerebral lactate also was associated with increased odds of death before discharge (OR: 1.75; P = 0.04).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CHD is associated with altered cerebral metabolites in utero, particularly in the third trimester period of pregnancy, which is characterized by exponential brain growth and maturation, and is associated with survival to hospital discharge. The long-term neurodevelopmental consequences of these findings warrant further study.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37821172/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37821172</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.013>10.1016/j.jacc.2023.08.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37821172</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Nickie N Andescavage</dc:creator>
<dc:creator>Subechhya Pradhan</dc:creator>
<dc:creator>Alexis C Gimovsky</dc:creator>
<dc:creator>Kushal Kapse</dc:creator>
<dc:creator>Mary T Donofrio</dc:creator>
<dc:creator>Jenhao Jacob Cheng</dc:creator>
<dc:creator>Yushuf Sharker</dc:creator>
<dc:creator>David Wessel</dc:creator>
<dc:creator>Adre J du Plessis</dc:creator>
<dc:creator>Catherine Limperopoulos</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Magnetic Resonance Spectroscopy of Brain Metabolism in Fetuses With Congenital Heart Disease</dc:title>
<dc:identifier>pmid:37821172</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.013</dc:identifier>
</item>
<item>
<title>Cardiac PET Perfusion Imaging: AURORA Lights the Way to a New Era</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37821171/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 17;82(16):1611-1613. doi: 10.1016/j.jacc.2023.08.032.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37821171/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37821171</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.032>10.1016/j.jacc.2023.08.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37821171</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jamieson M Bourque</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiac PET Perfusion Imaging: AURORA Lights the Way to a New Era</dc:title>
<dc:identifier>pmid:37821171</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.032</dc:identifier>
</item>
<item>
<title>Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37821170/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: This second flurpiridaz PET myocardial perfusion imaging trial shows that flurpiridaz has utility as a new tracer for CAD detection, specifically in women and obese patients. (An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz [18F] Injection PET MPI in the Detection of Coronary Artery Disease [CAD]; NCT03354273).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 17;82(16):1598-1610. doi: 10.1016/j.jacc.2023.08.016.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Flurpiridaz F-18 (flurpiridaz) is a novel positron emission tomography (PET) myocardial perfusion imaging tracer.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to further assess the diagnostic efficacy and safety of flurpiridaz for the detection and evaluation of coronary artery disease (CAD) defined as ≥50% stenosis by quantitative invasive coronary angiography (ICA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this second phase 3 prospective multicenter clinical study, 730 patients with suspected CAD from 48 clinical sites in the United States, Canada, and Europe were enrolled. Patients underwent 1-day rest/stress flurpiridaz PET and 1- or 2-day rest-stress Tc-99m-labeled single photon emission computed tomography (SPECT) before ICA. PET and SPECT images were read by 3 experts blinded to clinical and ICA data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 578 patients (age 63.7 ± 9.5 years) were evaluable; 32.5% were women, 52.3% had body mass index ≥30 kg/m<sup>2</sup>, and 33.6% had diabetes. Flurpiridaz PET met the efficacy endpoints of the study; its sensitivity and specificity were significantly higher than the prespecified threshold value by 2 of the 3 readers. The sensitivity of flurpiridaz PET was higher than SPECT (80.3% vs 68.7%; P = 0.0003) and its specificity was noninferior to SPECT (63.8% vs 61.7%; P = 0.0004). PET area under the receiver-operating characteristic curves were higher than SPECT in the overall population (0.80 vs 0.68; P &lt; 0.001), women, and obese patients (P &lt; 0.001 for both). Flurpiridaz PET was superior to SPECT (P &lt; 0.001) for perfusion defect size/severity evaluation, image quality, diagnostic certainty, and radiation exposure. Flurpiridaz PET was safe and well tolerated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This second flurpiridaz PET myocardial perfusion imaging trial shows that flurpiridaz has utility as a new tracer for CAD detection, specifically in women and obese patients. (An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz [18F] Injection PET MPI in the Detection of Coronary Artery Disease [CAD]; NCT03354273).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37821170/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37821170</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.016>10.1016/j.jacc.2023.08.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37821170</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jamshid Maddahi</dc:creator>
<dc:creator>Denis Agostini</dc:creator>
<dc:creator>Timothy M Bateman</dc:creator>
<dc:creator>Jeroen J Bax</dc:creator>
<dc:creator>Rob S B Beanlands</dc:creator>
<dc:creator>Daniel S Berman</dc:creator>
<dc:creator>Sharmila Dorbala</dc:creator>
<dc:creator>Ernest V Garcia</dc:creator>
<dc:creator>James Feldman</dc:creator>
<dc:creator>Gary V Heller</dc:creator>
<dc:creator>Juhani M Knuuti</dc:creator>
<dc:creator>Pedro Martinez-Clark</dc:creator>
<dc:creator>Matthieu Pelletier-Galarneau</dc:creator>
<dc:creator>Benjamin Shepple</dc:creator>
<dc:creator>Nagara Tamaki</dc:creator>
<dc:creator>Francois Tranquart</dc:creator>
<dc:creator>James E Udelson</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease</dc:title>
<dc:identifier>pmid:37821170</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.016</dc:identifier>
</item>
<item>
<title>Type 2 Diabetes Mellitus: Now in the Cardiologist's Wheelhouse</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37821169/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 17;82(16):1595-1597. doi: 10.1016/j.jacc.2023.08.033.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37821169/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37821169</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.033>10.1016/j.jacc.2023.08.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37821169</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Michael J Blaha</dc:creator>
<dc:creator>Michael Khorsandi</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Type 2 Diabetes Mellitus: Now in the Cardiologist's Wheelhouse</dc:title>
<dc:identifier>pmid:37821169</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.033</dc:identifier>
</item>
<item>
<title>10-Year Cardiovascular Risk in Patients With Newly Diagnosed Type 2 Diabetes Mellitus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37821168/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Newly diagnosed T2DM increased 10-year CVD risk across both sexes and all age groups, especially among younger patients, with CVD occurring ≤12 years earlier than in general population individuals.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 17;82(16):1583-1594. doi: 10.1016/j.jacc.2023.08.015.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Contemporary data on cardiovascular disease (CVD) risk in patients with newly diagnosed type 2 diabetes mellitus (T2DM) is needed to guide appropriate preventive management.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors sought to investigate sex- and age-specific 10-year CVD risk in patients with newly diagnosed T2DM compared with the general population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A cohort study was conducted of all Danish patients with T2DM diagnosed between 2006 and 2013 (n = 142,587) and sex- and age-matched individuals from the general population (n = 388,410), all without prior atherosclerotic CVD. Ten-year CVD risk (myocardial infarction, stroke, and fatal CVD) was estimated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 52,471 CVD events were recorded. Compared with the general population, the 10-year CVD risks were higher in patients with T2DM in both sexes and across all age groups, especially among younger individuals. For example, patients aged 40 to 49 years had the largest 10-year CVD risk difference (T2DM 6.1% vs general population 3.3%; risk difference: 2.8%, subdistribution HR: 1.91; 95% CI: 1.76-2.07). The age when a given CVD risk was reached differed substantially between the cohorts. Thus, a 10-year CVD risk of 5% was reached at age 43 in men with T2DM compared with 12 years later, at age 55, in men without T2DM. A 10-year CVD risk of 5% was reached at age 51 in women with T2DM and 10 years later, at age 61, in women without T2DM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Newly diagnosed T2DM increased 10-year CVD risk across both sexes and all age groups, especially among younger patients, with CVD occurring ≤12 years earlier than in general population individuals.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37821168/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37821168</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.015>10.1016/j.jacc.2023.08.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37821168</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Christine Gyldenkerne</dc:creator>
<dc:creator>Martin Bødtker Mortensen</dc:creator>
<dc:creator>Johnny Kahlert</dc:creator>
<dc:creator>Pernille Gro Thrane</dc:creator>
<dc:creator>Kevin Kris Warnakula Olesen</dc:creator>
<dc:creator>Henrik Toft Sørensen</dc:creator>
<dc:creator>Reimar Wernich Thomsen</dc:creator>
<dc:creator>Michael Maeng</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>10-Year Cardiovascular Risk in Patients With Newly Diagnosed Type 2 Diabetes Mellitus</dc:title>
<dc:identifier>pmid:37821168</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.015</dc:identifier>
</item>
<item>
<title>Long-Term Clopidogrel Monotherapy After Percutaneous Coronary Intervention: Will the Pupil Surpass the Master?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37821167/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 17;82(16):1579-1582. doi: 10.1016/j.jacc.2023.08.035.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37821167/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37821167</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.035>10.1016/j.jacc.2023.08.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37821167</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Luis Ortega-Paz</dc:creator>
<dc:creator>Manel Sabaté</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Term Clopidogrel Monotherapy After Percutaneous Coronary Intervention: Will the Pupil Surpass the Master?</dc:title>
<dc:identifier>pmid:37821167</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.035</dc:identifier>
</item>
<item>
<title>Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37821166/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: The beneficial effect of clopidogrel over aspirin monotherapy was consistent regardless of clinical risk or relative ischemic and bleeding risks compared with aspirin monotherapy. (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy [HOST-EXAM]; NCT02044250).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 17;82(16):1565-1578. doi: 10.1016/j.jacc.2023.07.031.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Clopidogrel was superior to aspirin monotherapy in secondary prevention after percutaneous coronary intervention (PCI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to evaluate the benefits of clopidogrel across high-risk subgroups METHODS: This was a post hoc analysis of the HOST-EXAM (Harmonizing Optimal Strategy for Treatment of coronary artery diseases-EXtended Antiplatelet Monotherapy) trial that randomly assigned patients who were event free for 6 to 18 months post-PCI on dual antiplatelet therapy (DAPT) to clopidogrel or aspirin monotherapy. Two clinical risk scores were used for risk stratification: the DAPT score and the Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention (TRS 2°P) (the sum of age ≥75 years, diabetes, hypertension, current smoking, peripheral artery disease, stroke, coronary artery bypass grafting, heart failure, and renal dysfunction). The primary composite endpoint was a composite of all-cause death, nonfatal myocardial infarction, stroke, readmission because of acute coronary syndrome, and major bleeding (Bleeding Academic Research Consortium type ≥3) at 2 years after randomization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 5,403 patients, clopidogrel monotherapy showed a lower rate of the primary composite endpoint than aspirin monotherapy (HR: 0.73; 95% CI: 0.59-0.90). The benefit of clopidogrel over aspirin was consistent regardless of TRS 2°P (high TRS 2°P [≥3] group: HR: 0.65 [95% CI: 0.44-0.96]; and low TRS 2°P [&lt;3] group: HR: 0.77 [95% CI: 0.60-0.99]) (P for interaction = 0.454) and regardless of DAPT score (high DAPT score [≥2] group: HR: 0.68 [95% CI: 0.46-1.00]; and low DAPT score [&lt;2] group: HR: 0.75 [95% CI: 0.59-0.96]) (P for interaction = 0.662). The association was similar for the individual outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The beneficial effect of clopidogrel over aspirin monotherapy was consistent regardless of clinical risk or relative ischemic and bleeding risks compared with aspirin monotherapy. (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy [HOST-EXAM]; NCT02044250).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37821166/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37821166</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.031>10.1016/j.jacc.2023.07.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37821166</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Seokhun Yang</dc:creator>
<dc:creator>Jeehoon Kang</dc:creator>
<dc:creator>Kyung Woo Park</dc:creator>
<dc:creator>Seung-Ho Hur</dc:creator>
<dc:creator>Nam Ho Lee</dc:creator>
<dc:creator>Doyeon Hwang</dc:creator>
<dc:creator>Han-Mo Yang</dc:creator>
<dc:creator>Hyo-Suk Ahn</dc:creator>
<dc:creator>Kwang Soo Cha</dc:creator>
<dc:creator>Sang-Ho Jo</dc:creator>
<dc:creator>Jae Kean Ryu</dc:creator>
<dc:creator>Il-Woo Suh</dc:creator>
<dc:creator>Hyun-Hee Choi</dc:creator>
<dc:creator>Seong-Ill Woo</dc:creator>
<dc:creator>Jung-Kyu Han</dc:creator>
<dc:creator>Eun-Seok Shin</dc:creator>
<dc:creator>Bon-Kwon Koo</dc:creator>
<dc:creator>Hyo-Soo Kim</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks</dc:title>
<dc:identifier>pmid:37821166</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.031</dc:identifier>
</item>
<item>
<title>Cardio-Oncology Rehabilitation Programs-The Next Phase in Improving Care for Cancer Survivors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37819675/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 11. doi: 10.1001/jamacardio.2023.3568. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37819675/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37819675</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3568>10.1001/jamacardio.2023.3568</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37819675</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Nausheen Akhter</dc:creator>
<dc:creator>Susan Dent</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Cardio-Oncology Rehabilitation Programs-The Next Phase in Improving Care for Cancer Survivors</dc:title>
<dc:identifier>pmid:37819675</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3568</dc:identifier>
</item>
<item>
<title>Mitochondrial Respiration and Exercise Performance in Patients With Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37819670/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 11. doi: 10.1001/jamacardio.2023.3574. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37819670/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37819670</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3574>10.1001/jamacardio.2023.3574</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37819670</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Johannes Burtscher</dc:creator>
<dc:creator>Martin Burtscher</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Mitochondrial Respiration and Exercise Performance in Patients With Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:37819670</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3574</dc:identifier>
</item>
<item>
<title>Concordance of a High Lipoprotein(a) Concentration Among Relatives</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37819667/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231012081516&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: The findings of this cross-sectional study suggest that the yield of cascade screening of first-degree relatives of individuals with high Lp(a) levels is over 40%. These findings support recent recommendations to use this approach to identify additional individuals at ASCVD risk based on Lp(a) concentrations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 11. doi: 10.1001/jamacardio.2023.3548. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Lipoprotein(a) (Lp[a]) concentrations are a highly heritable and potential causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Recent consensus statements by the European Atherosclerosis Society and American Heart Association recommend screening of relatives of individuals with high Lp(a) concentrations, but the expected yield of this approach has not been quantified in large populations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To measure the prevalence of high Lp(a) concentrations among first- and second-degree relatives of individuals with high Lp(a) concentrations compared with unrelated participants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: In this cross-sectional analysis, pairs of first-degree (n = 19 899) and second-degree (n = 9715) relatives with measured Lp(a) levels from the UK Biobank study and random pairs of unrelated individuals (n = 184 764) were compared. Data for this study were collected from March 2006 to August 2010 and analyzed from December 2021 to August 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Serum Lp(a) levels, with a high Lp(a) level defined as at least 125 nmol/L.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURE: Concordance of clinically relevant high Lp(a) levels in first- and second-degree relatives of index participants with high Lp(a) levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 52 418 participants were included in the analysis (mean [SD] age, 57.3 [8.0] years; 29 825 [56.9%] women). Levels of Lp(a) were correlated among pairs of first-degree (Spearman ρ = 0.45; P &lt; .001) and second-degree (Spearman ρ = 0.22; P &lt; .001) relatives. A total of 1607 of 3420 (47.0% [95% CI, 45.3%-48.7%]) first-degree and 514 of 1614 (31.8% [95% CI, 29.6%-34.2%]) second-degree relatives of index participants with high Lp(a) levels also had elevated concentrations compared with 4974 of 30 258 (16.4% [95% CI, 16.0%-16.9%]) pairs of unrelated individuals. The concordance in high Lp(a) levels was generally consistent among subgroups (eg, those with prior ASCVD, postmenopausal women, and statin users). The odds ratios for relatives to have high Lp(a) levels if their index relative had a high Lp(a) level compared with those whose index relatives did not have high Lp(a) levels were 7.4 (95% CI, 6.8-8.1) for first-degree relatives and 3.0 (95% CI, 2.7-3.4) for second-degree relatives.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: The findings of this cross-sectional study suggest that the yield of cascade screening of first-degree relatives of individuals with high Lp(a) levels is over 40%. These findings support recent recommendations to use this approach to identify additional individuals at ASCVD risk based on Lp(a) concentrations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37819667/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231012081516&v=2.17.9.post6+86293ac">37819667</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3548>10.1001/jamacardio.2023.3548</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37819667</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Laurens F Reeskamp</dc:creator>
<dc:creator>Tycho R Tromp</dc:creator>
<dc:creator>Aniruddh P Patel</dc:creator>
<dc:creator>Shirin Ibrahim</dc:creator>
<dc:creator>Mark Trinder</dc:creator>
<dc:creator>Sara Haidermota</dc:creator>
<dc:creator>G Kees Hovingh</dc:creator>
<dc:creator>Erik S G Stroes</dc:creator>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>Amit V Khera</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Concordance of a High Lipoprotein(a) Concentration Among Relatives</dc:title>
<dc:identifier>pmid:37819667</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3548</dc:identifier>
</item>





























</channel>
</rss>